Here, we demonstrated that blocking cytokine signaling using a JAK2 inhibitor in combination with imatinib might be an effective strategy to eradicate residual CML cells in vitro and in vivo. The gene discussed is JAK2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.